REFERENCES
1. Vandenplas O, Vinnikov D, Blanc PD, et al. Impact of Rhinitis on Work
Productivity: A Systematic Review. J Allergy Clin Immunol Pract .
2018 Jul-Aug;6(4):1274-1286.
2. Wheatley L, Togias A. Clinical practice. Allergic rhinitis . N
Engl J Med. 2015 Jan 29;372(5):456-63.
3. Hossenbaccus L, Linton S, Garvey S, Ellis AK. Towards definitive
management of allergic rhinitis: best use of new and established
therapies. Allergy Asthma Clin Immunol . 2020 May 27;16:39.
4. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody
directed against IgE. J Immunol . 1993 Sep 1;151(5):2623-32.
5. Casale TB. Anti-immunoglobulin E (omalizumab) therapy in seasonal
allergic rhinitis. Am J Respir Crit Care Med . 2001 Oct 15;164(8
Pt 2):S18-21.
6. Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the
treatment of inadequately controlled allergic rhinitis: a systematic
review and meta-analysis of randomized clinical trials. J Allergy
Clin Immunol Pract . 2014 May-Jun;2(3):332-40.e1.
7. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane
Collaboration’s tool for assessing risk of bias in randomised trials.BMJ . 2011 Oct 18;343:d5928.
8. Bez C, Schubert R, Kopp M, et al. Effect of anti-immunoglobulin E on
nasal inflammation in patients with seasonal allergic
rhinoconjunctivitis. Clin Exp Allergy . 2004;34(7):1079-85.
9. Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. The co-seasonal
application of anti-IgE after preseasonal specific immunotherapy
decreases ocular and nasal symptom scores and rescue medication use in
grass pollen allergic children. Allergy . 2004 Sep;59(9):973-9.
10. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination
treatment with anti-IgE plus specific immunotherapy in polysensitized
children and adolescents with seasonal allergic rhinitis. J
Allergy Clin Immunol . 2002;109(2):274-80.
11. Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and
specific immunotherapy is superior to immunotherapy in patients with
seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic
asthma. Clin Exp Allergy . 2009;39(2):271-9.
12. Nagakura T, Ogino S, Okubo K, Sato N, Takahashi M, Ishikawa T.
Omalizumab is more effective than suplatast tosilate in the treatment of
Japanese cedar pollen-induced seasonal allergic rhinitis. Clin Exp
Allergy . 2008;38(2):329-37.
13. Okubo K, Ogino S, Nagakura T, Ishikawa T. Omalizumab is effective
and safe in the treatment of Japanese cedar pollen-induced seasonal
allergic rhinitis. Allergol Int . 2006;55(4):379-86.
14. Okubo K, Okano M, Sato N, et al. Add-On Omalizumab for Inadequately
Controlled Severe Pollinosis Despite Standard-of-Care: A Randomized
Study. J Allergy Clin Immunol Pract . 2020;8(9):3130-40 e2.
15. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25,
an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.J Allergy Clin Immunol . 2000;106(2):253-9.
16. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE
antibody, in the treatment of adults and adolescents with perennial
allergic rhinitis. Ann Allergy Asthma Immunol . 2003
Aug;91(2):160-7.
17. Higaki T, Okano M, Kariya S, et al. Determining minimal clinically
important differences in Japanese cedar/cypress pollinosis
patients. Allergol Int . 2013 Dec;62(4):487-93.
18. Okubo K, Kurono Y, Ichimura K, et al. Japanese guidelines for
allergic rhinitis 2020. Allergol Int . 2020 Jul;69(3):331-345.
19. Nakamura S, Tsunoda S, Sakaida H, Masuda S, Said AS, Takeuchi K.
Analysis of factors associated with cedar pollen sensitization and
development of pollinosis in a young Japanese adult population.Allergol Int . 2019 Jan;68(1):39-45.
20. Gotoh M, Yuta A, Okano M, Ohta N, Ohta N, Matsubara A, Matsubara A,
Okubo K. Severity assessment of Japanese cedar pollinosis using the
practical guideline for the management of allergic rhinitis in Japan and
the allergic rhinitis and its impact on asthma guideline. Allergol
Int . 2013 Jun;62(2):181-9.
21. Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment
decreases acute reactions after rush immunotherapy for ragweed-induced
seasonal allergic rhinitis. J Allergy Clin Immunol .
2006;117(1):134-40.
22. Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of
anti-IgE treatment with omalizumab in children with seasonal allergic
rhinitis undergoing specific immunotherapy simultaneously. Pediatr
Allergy Immunol . 2010;21(1 Pt 2):e160-5.
23. New Drugs Approved in FY 2019. Available at:https://www.pmda.go.jp/files/000235289.pdf
24. Yu C, Wang K, Cui X, et al. Clinical Efficacy and Safety of
Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review
and Meta-analysis of Randomized Clinical Trials. Am J Rhinol
Allergy . 2020 Mar;34(2):196-208.
25. Cavaliere C, Begvarfaj E, Incorvaia C, et al. Long-term omalizumab
efficacy in allergic rhinitis. Immunol Lett . 2020 Nov;227:81-87
26. Casale TB, Bernstein Il, Busse WW, et al. Use of an anti-IgE
humanized monoclonal antibody in ragweed-induced allergic rhinitis.J Allergy Clin Immunol . 1997 Jul;100(1):110-21
27. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on
symptoms of seasonal allergic rhinitis: a randomized controlled trial.JAMA . 2001 Dec 19;286(23):2956-67.
28. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability
of anti-immunoglobulin E therapy with omalizumab in patients with
concomitant allergic asthma and persistent allergic rhinitis:
SOLAR. Allergy . 2004 Jul;59(7):709-17.
Table I General Characteristics of included studies